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The guardian of the genome (p53) elicits cell-cycle checkpoints in response to genotoxic stress. p53 also
induces a metabolic checkpoint by inhibiting the mammalian target of rapamycin complex 1 (mTORC1). Re-
cent results by Budanov and Karin, (2008) reveal that p53 exerts its effect on mTORC1 through sestrin1 and
sestrin2.The tumor suppressor p53 is a sensor of
genotoxic stress that protects cells from
DNA damage by inducing cell-cycle ar-
rest. However, cell cycle-arrested cells
may maintain other metabolic processes
at a relatively high rate, unless a process
that coordinates and couples cell-cycle
arrest and metabolic arrest is imple-
mented. It appears that p53 is capable of
implementing such a process by inhibiting
the major regulator of protein synthesis,
mammalian target of rapamycin complex
1 (mTORC1). Since protein synthesis is
a major determinant of cell mass, and
therefore a major consumer of cellular
energy, the inhibition of mTORC1 by p53
synchronizes cell-cycle arrest, cell mass,
and energy consumption to maintain
cellular homeostasis. In addition, since
mTORC1 is also a positive regulator of
cell proliferation, the inhibition of mTORC1
by p53 further facilitates cell-cycle arrest.
The mechanism by which p53 exerts its
effect on mTORC1 has been recently ad-
dressed (Budanov and Karin, 2008).
mTORC1 induces protein synthesis by
the phosphorylation and inactivation of
the eukaryotic initiation factor 4E (eIF4E)
binding protein (4E-BP1) and through the
phosphorylation and activation of S6 ki-
nase (S6K1) (Hay and Sonenberg, 2004).
mTORC1 comprises mTOR, Raptor, and
mLST8, and its activity is regulated by
an array of extracellular and environmen-
tal signals. Most of these signals exert
their effect on mTORC1 by modulating
the activity of the tuberous sclerosis com-
plex proteins, TSC1 and TSC2, which
form a heterodimer that functions as
a GTPase activating protein (GAP) to in-
hibit the activity of the small GTPase
Rheb (Bhaskar and Hay, 2007). As Rheb
is required for the activity of mTORC1,
the modulation of TSC1/TSC2 hetero-
dimer activity by extracellular signals184 Cell Metabolism 8, September 3, 2008 ªalso modulates mTORC1 activity. For in-
stance, upon energy stress, the sensor
of intracellular ATP levels, AMP-activated
kinase (AMPK), is activated to phosphory-
late and activate TSC2, thereby inhibiting
mTORC1.
p53 has been shown previously to in-
hibit mTORC1 activity by elevating
AMPK activity (Levine et al., 2006). How-
ever, the mechanism by which p53 ele-
vates the activity of AMPK remained elu-
sive. The recent work by Budanov and
Karin (Budanov and Karin, 2008) un-
covers the mechanism by which p53 re-
cruits AMPK to inhibit mTORC1. AMPK
exists as a heterotrimeric complex com-
prising catalytic a-subunits and regula-
tory b- and g-subunits. The catalytic a1
and a2 subunits are activated by the
phosphorylation of Thr172. The binding
of AMP, which is antagonized by the
binding of ATP, to the g-subunit, elicits
an allosteric change in the heterotrimeric
complex that promotes the phosphoryla-
tion and inhibits the dephosphorylation of
Thr172. The major kinase that phosphor-
ylates Thr172 is LKB1, but it can also be
phosphorylated by at least two other ki-
nases, Ca2+/Calmodulin-activated kinase
(CaMKK) and the transforming growth-
factor b-activated kinase (TAK1) (Hardie,
2007) (Figure 1).
Budanov and Karin now show that
AMPK can be phosphorylated and acti-
vated by binding to sestrin1 (Sesn1) or
sestrin2 (Sesn2), which are p53 target
genes. Sestrins are an evolutionarily con-
served family of proteins (Budanov et al.,
2002; Velasco-Miguel et al., 1999). Mam-
malian cells express three members of
this family, Sesn1–3, which have been
shown to decrease intracellular ROS and
to confer resistance to oxidative stress,
probably by regenerating overoxidized
peroxiredoxins that deoxidize reactive2008 Elsevier Inc.oxygen species (ROS) (Budanov et al.,
2004). Sesn1 and Sesn2 expression, ele-
vated by p53 in response to genotoxic
stress, has been shown to be responsible
for the resistance to oxidative stress in-
duced by p53 both in vitro and in vivo
(Budanov et al., 2002; Matheu et al.,
2007; Sablina et al., 2005). It appears
that Sesn1/2 interact with the a-catalytic
subunits of AMPK. This interaction in-
creases AMPK phosphorylation and in-
duces its activity. The ability of Sesn1/2
to activate AMPK is independent of their
redox activity. Surprisingly, the activation
of AMPK by Sesn1/2 is independent of
the intracellular ATP level and of LKB1.
Thus, Sesn1/2 interaction may facilitate
phosphorylation of AMPK at Thr172 by an-
other kinase, inhibit dephosphorylation of
Thr172, or induce autophosphorylation,
as suggested by Budanov and Karin (Fig-
ure 1). Importantly, Sesn1/2 preferentially
activate AMPK toward the phosphoryla-
tion of TSC2, as they also bind TSC2 and
therefore, tether AMPK to TSC2 (Figure 1).
The recent study shows that p53 acti-
vation by genotoxic stress could emulate
a response to metabolic stress by activat-
ing AMPK. Previous studies have shown
a reciprocal interplay between genotoxic
stress and metabolic stress (Levine
et al., 2006), as the activation of AMPK
by metabolic stress results in the phos-
phorylation of p53’s Ser 15, leading to
p53 activation (Levine et al., 2006; Fig-
ure 1). The results presented by Budanov
and Karin imply that a metabolic stress in
the presence of p53 should have a more
substantial inhibitory effect on mTORC1
than in the absence of p53. In the absence
of p53, AMPK activation by metabolic
stress mediates the phosphorylation and
activation of TSC2. However, in the pres-
ence of p53, activating AMPK via meta-
bolic stress should amplify the activation
Cell Metabolism
PreviewsFigure 1. A Figure Depicting Interplays between Genotoxic Stress and Metabolic Stress
Genotoxic stress activates p53, which in turn induces the transcription and expression of sestrin1 and ses-
trin2. Sestrin1 or sestrin2 then binds to AMPK and induces the phosphorylation and activity of the a-cat-
alytic subunit of AMPK. Sestrin1 or sestrin2 form a complex between AMPK and TSC2 that promotes
phosphorylation of TSC2 and activation of TSC1/TSC2 GAP activity toward Rheb, thereby inhibiting
mTORC1 and, consequently, cell growth and proliferation, while activating autophagy. The mechanism
by which Sesn1/2 induce the phosphorylation and activation of AMPK remains elusive (potential mecha-
nisms are depicted with a question mark). The activation of AMPK by metabolic stress may lead to the
activation of p53 and, therefore, further facilitates the inhibition of mTORC1 (see text for details).of TSC2 via the newly discovered mecha-
nism. Furthermore, if the activation of
AMPK by Sesn1/2 can also increase
Ser15 phosphorylation of p53, it might
elicit a positive regulatory loop that would
further increase the activation of TSC2
and the inhibition of mTORC1.
Budanov and Karin also show that
Sesn1/2 have a tumor suppressor func-
tion, as they inhibit oncogenic transforma-
tion by inhibiting mTORC1. mTORC1 has
been shown to be required for oncogenic
transformation, in particular for Akt-de-
pendent transformation (Skeen et al.,
2006). Thus, Sesn1/2 could be used as
a therapeutic regimen for cancer cells
that display Akt activation due to PTEN
deficiency or PI3K activation.
The new study, while discovering an im-
portant link between genotoxic stress and
mTORC1 activity, also raises several new
questions. For instance, the exact mecha-nistic activation of AMPK by Sesn1/2, in
particular the mechanism by which
Sesn1/2 binding increases AMPK phos-
phorylation, is still unknown (Figure 1). It
is not known whether only the catalytic
a-subunit of AMPK is coimmunoprecipi-
tated with Sesn1/2, or also the b- and
g-regulatory subunits. Likewise, it is not
clear whether Sesn1/2 bind directly to
the a-subunit of AMPK or indirectly
through interaction with the b- or g-sub-
unit. If Sesn1/2 interact with the g-sub-
unit, is it possible that they act as AMP
mimetic? In addition, the sequence of
events leading to the activation of AMPK
toward TSC2 is not well understood. It is
not clear whether the complex AMPK/
Sesn1/2/TSC2 is formed simultaneously,
or if the binding of AMPK to Sesn1/2 and
its subsequent activation occurs first, fol-
lowed by the tethering of the activated
AMPK to TSC2. Finally, it was shown pre-Cell Metabolism 8,viously that the phosphorylation of TSC2
by AMPK is in fact priming for the phos-
phorylation of TSC2 by GSK3, which is re-
quired for the activation of TSC2 (Inoki
et al., 2006). It is not known if the phos-
phorylation of TSC2 by the Sesn1/2/
AMPK complex also requires phosphory-
lation by GSK3 to activate TSC2, or the
Sesn1/2/AMPK complex phosphorylates
TSC2 at different sites and activates
TSC2 independently of GSK3. Clearly
more work is required to address these
questions. Thus, the recent breakthrough
in the understanding of the p53/AMPK/
mTORC1 axis may also open a window
for additional intriguing discoveries.
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